Conference Service Mandl

abstract: Pharmacy as a profession is currently undergoing a period of unprecedented change, and pharmacy education needs to reflect this. Legislative and other initiatives will have an impact on how and what we teach students, and even more radically, how we assess competencies required to produce the successful pharmacists of the future. This meeting is intended to bring together policymakers and academics to discuss how best the necessary changes can be introduced, and to exchange ideas of best practice.

abstract: The RPSGB and FIP are pleased to present the return of the Quality International conference for 2010. The conference will explore the process of supplying patients with quality drugs through the supply chain of drug development, industrial manufacturing, distribution and hospital and retail pharmacy dispensing. The key shift in managing quality of medicines in recent years was the introduction of new GMPs for the 21st century and also the initiation of the Quality by Design concept throughout drug development and manufacture. While there have been many conferences on quality concepts, these usually focused on certain aspects of quality in distinct phases of the supply chain such as R&D, manufacturing or distribution. However, it is of paramount importance to understand the impact of quality on the end user - patients. Without such broad understanding the efforts and resources spent on managing quality in isolation in each phase of drug development & distribution can become blurred. Therefore, this conference will be a first time look at the holistic concept of ‘quality of drugs’ to patients!

abstract: The course is comprised of lectures, delivered by leading experts in each field of ADME, interspersed with interactive workshops centred around practical examples demonstrating how in vitro data generated during drug development can be used to predict:

• Metabolic drug clearance (CL)
• Metabolic drug-drug interactions (DDIs)
• Gut first-pass metabolism
• Oral drug absorption incorporating food effects and the impact of dosage form
• Effect of transporters and enterohepatic recirculation on kinetics
• Drug distribution to different organs
• Population variability in drug concentration-time profiles
• Variation in kinetics in specific populations (paediatrics, ethnic groups, various disease populations)
• Time-course of drug in plasma that fits observed clinical data (achieved using fitting modules within physiologically-based pharmacokinetics (PBPK) models combined with drug specific in vitro information.)

abstract: European legislation and guidelines such as Volume 9A require all marketing authorisation holders to have a Qualified Person for Pharmacovigilance (QPPV) with responsibility for establishing and maintaining all aspects of the company’s global pharmacovigilance system. Although acknowledged to be a vital function, there is little practical guidance on how QPPV responsibilities should best be conducted, while maintaining compliance with regulatory requirements, particularly in complex or challenging situations. The jurisdiction of the QPPV stretches to wherever there is an active licence for a product authorised in the EU. Thus the role in many companies has a far reaching impact outside the EU or may extend to products licensed by one or more affiliates or subject to co-marketing agreements. During this meeting we will discuss and draw on experience of handling these situations in the current complex environment to help QPPVs perform their job more efficiently.

abstract: The 2nd Annual Drug Development Congress 2010, presented by Oxford Global Conferences, will provide a first class educational and networking opportunity for over 120 attendees. Do not miss out on this opportunity to gain new insight on how to effectively manage and streamline your Early Development process. Over the 2 days, the summit will feature key note addresses, case study presentations, and panel & roundtable discussions featuring over 40 senior level industry speakers from the leading pharmaceutical, biotechnology, diagnostics, clinical research and academic institutions, exploring hot topics.

abstract: The prudent application of relevant new technologies in medicinal chemistry is one way to increase the quality and efficiency of drug discovery. Everyone working in the pharmaceutical industry is very aware of the need for improved productivity. The cost of R&D continues to grow rapidly while the number of new drugs being brought to the market has dwindled which has led to the recent significant reductions in the in-house research efforts in large pharmaceutical companies. The RSC High Throughput Chemistry and New Technologies Group and SCI's Fine Chemicals Group have organised this one day symposium to highlight recent advances in technology-enabled drug discovery as well as new synthetic technologies with particular relevance to medicinal chemistry. This will be the sixth meeting in this symposium series.

abstract: This is the major international forum for the discussion of all technical aspects of scale-up at the chemistry/chemical engineering interface. Topics include: the scale up of batch and semi-batch processes, continuous processing and reaction engineering, microreactor technology, safety and thermochemistry, scale up of potentially hazardous chemistry, green chemistry, quality assurance and regulatory concerns, solid form control (crystallisation and polymorphism), separation and purification techniques, and new technologies and equipment for large scale manufacture.

abstract: This ever-popular 3-day training course for chemists and engineers in industry aims to discuss the most efficient methods for developing cheap, robust processes. It covers the principles of scale-up and development and provides examples and case studies from industry. Not to be missed if you are just starting work in chemical development and a useful refresher for more experienced development chemists!

abstract: To support the supply of safe and effective medicines, consideration must be given to the stability of the ingredients and the product during the development, manufacture, storage, distribution and use of pharmaceutical products.

This symposium will explore critical issues encountered in both hospital and industry with medicines designed for special populations. The techniques used to characterise and understand pharmaceutical systems, and approaches that can be taken to predict stability will be described. Speakers will discuss stability issues and concerns encountered during the development and supply of biological products, with medicines for paediatrics, during manufacture of aseptic products and in the provision of other unlicensed medicines.

The programme includes contributions from key industrial, hospital, academic and regulatory speakers.

abstract: Welcome to the 2nd annual World Biobanking Summit and exhibition. This year's event will be held in the historic city of Edinburgh during the world famous Festival Fringe allowing the opportunity to arrive early and enjoy the events. The conference will be co-located with Stem Cells Europe and Cellular Therapy Summit. Registered delegates will have access to all three meetings ensuring a very cost-effective trip. Agenda Topics Sample Collection & Storage Automation Quality Assurance Bioethics & Regulations Harmonization & Standardization Confirmed Speakers: Robert Hewitt CEO, Integrated Biobank of Luxembourg Mary Beth Fisk Vice President, Texas Blood and Tissue Bank

abstract: Welcome to the 3rd annual Stem Cells Europe conference. This year's event will be held in the historic city of Edinburgh during the world famous Festival Fringe allowing the opportunity to arrive early and enjoy the events. The agenda will reflect the dynamic nature of the field as we move from fundamental stem cell research towards clinical therapies. The conference will be co-located with the World Biobanking Summit and Cellular Therapy Summit. Registered delegates will have access to all three meetings ensuring a very cost-effective trip. Confirmed Speakers: Sir John Gurdon, Gurdon Institute Michael Whitaker, Professor, Newcastle University Geoff Raisman Professor, University College London Karim Nayernia Professor, Newcastle University Andrei Novik Professor, National Medical Surgical Center Russia Agenda Topics: Advances in Tissue Engineering Regenerative Medicine Drug Discovery and Disease-Related Research Therapeutic Potential of Pluripotent Human Embryonic and Reprogrammed Somatic Stem Cells Epigenetics Commercialisation of Stem Cell Research Start-Up Case Studies Regulatory and IP Situation Bioethics Related to Stem Cells Funding Sources for Stem Cell Research

abstract: Welcome to the inaugural Cellular Therapy Summit, to be held in the historic city of Edinburgh during the world famous Festival Fringe allowing the opportunity to arrive early and enjoy the events. The conference will be co-located with Stem Cells Europe and World Biobanking Summit. Registered delegates will have access to all three meetings ensuring a very cost-effective trip. Confirmed Speakers: Peter Coffey Professor, University College London Lusine Danielyan University of Tuebingen Julie Daniels Lecturer, University College London Todd McCallister Cytograft Tissue Engineering Manzoor Mangi Director, Stemcellfix Biomimetic Therapy Agenda Topics Cellular Therapies for Cardiovascular Disease Cellular Therapies for CNS Disorders Development of Personalized Cellular Therapies Tissue Engineering

abstract: How can pharmacists best support patients in their healthcare decisions? How can the profession be supported in dealing with workplace and commercial pressures while maintaining commitment to high quality patient care? These are just some of the issues that the Royal Pharmaceutical Society will address at its new conference in 2010.

This brand new event will have a practice and professional focus and will explore patient and professional decision making - how pharmacists, as professionals, can lead the way in maximising the optimal use of medicines, maintaining the best interests of patients and in making the best possible decision during times of workplace stress. This is an opportunity for pharmacists to develop leadership skills and to network and see how such networking has been developed at local levels across the countries.